Research Analysts Offer Predictions for CRBU FY2030 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Equities research analysts at Brookline Capital Management issued their FY2030 earnings estimates for Caribou Biosciences in a research report issued to clients and investors on Wednesday, February 4th. Brookline Capital Management analyst L. Cann anticipates that the company will earn ($5.28) per share for the year. The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share.

A number of other equities research analysts also recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Caribou Biosciences in a research report on Wednesday, January 21st. Truist Financial set a $7.00 price objective on Caribou Biosciences in a research note on Tuesday, November 4th. Citigroup raised their target price on Caribou Biosciences from $5.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, November 3rd. Finally, HC Wainwright boosted their price target on shares of Caribou Biosciences from $3.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Caribou Biosciences currently has a consensus rating of “Hold” and an average target price of $8.00.

Caribou Biosciences Price Performance

NASDAQ CRBU opened at $1.48 on Friday. Caribou Biosciences has a 12 month low of $0.66 and a 12 month high of $3.54. The firm has a market capitalization of $138.34 million, a PE ratio of -0.87 and a beta of 2.61. The company’s 50 day simple moving average is $1.65 and its 200 day simple moving average is $1.94.

Caribou Biosciences (NASDAQ:CRBU) last released its earnings results on Wednesday, November 12th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.06. The firm had revenue of $2.20 million for the quarter, compared to analysts’ expectations of $1.94 million. Caribou Biosciences had a negative net margin of 1,690.45% and a negative return on equity of 69.85%.

Institutional Investors Weigh In On Caribou Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of CRBU. Next Capital Management LLC purchased a new stake in shares of Caribou Biosciences during the second quarter valued at $25,000. Bronte Capital Management Pty Ltd. purchased a new position in Caribou Biosciences in the 4th quarter worth about $25,000. Creative Planning acquired a new stake in Caribou Biosciences during the 2nd quarter worth about $25,000. R Squared Ltd acquired a new stake in Caribou Biosciences during the 3rd quarter worth about $29,000. Finally, Hudson Bay Capital Management LP purchased a new stake in Caribou Biosciences during the second quarter valued at about $30,000. 77.51% of the stock is owned by institutional investors and hedge funds.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.